21 states file lawsuit challenging 2027 ACA payment rule

By Alan Goforth – A coalition of attorneys general from 21 states, along with Pennsylvania Gov. Josh Shapiro, have filed a lawsuit challenging a federal rule that they allege undermines the Affordable Care Act and makes health insurance more expensive and harder to obtain for millions of Americans. The lawsuit seeks to block provisions of the Trump administration's ACA payment rule for 2027 health plans, which the same attorneys general previously opposed in a March comment letter. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Multistate Legal Challenge to 2027 ACA Rule: Attorneys general from 21 states, joined by Pennsylvania’s governor, have filed suit to block portions of the federal government’s 2027 ACA payment rule. The coalition argues that the regulation weakens the Affordable Care Act and increases costs while reducing access to coverage. They are asking the court to prevent the contested provisions from taking effect. The action follows earlier opposition outlined in a March comment letter.

2. Dispute Over Reinstated and Expanded Provisions: The plaintiffs contend that the 2027 rule revives elements of a previous regulation that a federal court had already vacated. They also object to an expansion of catastrophic health plans that they say exceeds statutory limits and allows certain plans to bypass legally established out-of-pocket maximums. In their view, these changes could push consumers toward less comprehensive coverage. The lawsuit claims the rulemaking process failed to adequately address prior objections.

3. Ongoing Legal and Political Conflict: State officials, including California Attorney General Rob Bonta and New Jersey Attorney General Jennifer Davenport, argue the administration’s policies are increasing financial strain on families. Meanwhile, the U.S. Department of Health and Human Services has appealed a separate Maryland court ruling that overturned part of an earlier rule. This sets up continued litigation over how ACA payment policies should be structured. The outcome could influence plan design standards and consumer protections in upcoming coverage years.

Mutual of Omaha and Claritev automate supplemental health claims filing

By Mark Rosanes – Mutual of Omaha's Workplace Solutions division and Claritev have agreed to integrate their platforms to automate the supplemental health benefits claims process. Claritev's medical claims data will identify policyholders eligible to file under accident, critical illness, or hospital indemnity coverage and notify them to do so. Read Full Article...

HVBA Article Summary

1. Automation aims to close the supplemental benefits utilization gap: The integration is designed to address low engagement with voluntary benefits, a persistent issue for employers and carriers. Industry research cited in the article shows that fewer than one in three employees fully use their supplemental coverage, and 13% are unaware they even have it. By scanning medical claims data for qualifying events and prompting employees to file, the service seeks to increase awareness and claims activity. The approach attempts to connect real-time health events with the benefits employees elected during open enrollment.

2. End-to-end claims support reduces friction during medical events: Mutual of Omaha describes the service as covering the entire claims cycle, from identifying potential eligibility to facilitating payment. Company executives from both firms emphasize that employees often struggle to navigate benefits while recovering from medical issues. Automating notifications and triggers is intended to reduce administrative burdens and speed up access to funds. Claritev brings scale to the collaboration, serving more than 750 healthcare payers, over 100,000 employers, and 60 million consumers with decades of claims processing experience.

3. Improved utilization could strengthen broker retention at renewal: The article highlights that brokers face retention challenges when employers see little evidence that employees are using purchased coverage. Automated claim triggers may help demonstrate tangible value without requiring additional communication efforts from employers. Showing documented claims activity can become a stronger element of renewal discussions. As healthcare costs rise, supplemental coverage is positioned as a cost-conscious enhancement to benefits packages, making measurable engagement increasingly important.

Prudential looks for domestic benefits deals amid global turmoil

By Allison Bell – Big U.S. insurers are responding to turmoil all over the world by shopping for comfort deals: acquisitions of companies that sell employee benefits products in the United States. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Shift Toward Domestic, Capital-Light Businesses: Major insurers including Prudential and MetLife are prioritizing U.S.-based employee benefits operations as global markets become more fragmented. Executives described group benefits as recurring-revenue and capital-light, making them attractive during periods of geopolitical and financial uncertainty. Rather than pursuing transformative mergers, companies signaled interest in targeted acquisitions that expand capabilities. This reflects a broader strategic recalibration toward steadier, domestically focused growth.

2. Active Deal Environment and Strategic Realignment: The Hartford’s agreement to acquire Equitable’s employee benefits business, which generates about $500 million annually, underscores renewed activity in the sector. At the same time, activist investors are pressuring firms such as CBIZ and Voya to pursue sales or strategic changes, contributing to a more dynamic M&A climate. Recent transactions, including multi-billion-dollar deals, suggest investor resistance to acquisitions may be easing. Insurers appear more willing to use capital for expansion rather than limiting themselves to dividends and share buybacks.

3. Long-Term Confidence in the Group Benefits Market: Prudential executives characterized the U.S. group benefits market as mature but stable, with expectations for low single-digit growth. Leadership emphasized that the business is highly cash-generative and diversifies overall company revenue streams. Employers’ ongoing commitment to offering robust benefits packages was cited as a supportive demand factor. Prudential believes it can gradually gain market share even in a slow-growth environment.

Ready for open enrollment? Here's how to prepare now

By Kevin Robertson – Open enrollment is just around the corner, and employer benefits teams and employees face important decisions. With rising healthcare costs and evolving expectations, clear and engaging communication to support employees in making informed decisions is critically important. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Benefits Influence Retention and Mobility: Employees increasingly view benefits as a deciding factor in whether to stay with or leave an employer. The 2025 HSA Bank Health & Wealth Index found that 42% of workers would consider changing jobs for better benefits, with that figure rising to 54% for Gen Z and 49% for millennials. Despite this, many employees devote limited time to their selections, spending an average of 18 minutes choosing benefits during open enrollment. This dynamic creates both risk and opportunity for employers to better align offerings with workforce expectations.

2. Confusion Drives Default Decisions: Research from HSA Bank shows that nearly three quarters of employees find the enrollment process confusing. As a result, 86% stick with the same health plan year after year, even when costs or personal circumstances shift. The article argues that HR teams can counter this tendency by offering decision-support tools, cost calculators and clearer comparisons. More accessible education and structured communication can help employees reassess options rather than defaulting to the familiar.

3. Targeted Communication and Support Improve Engagement: With multigenerational workforces, employers are encouraged to tailor messaging to different employee segments instead of relying on broad, one-size-fits-all campaigns. The Health and Wealth Index notes that 60% of employees say side-by-side health plan comparisons would make enrollment easier, underscoring the demand for clarity. The author recommends user-friendly platforms, off-cycle rollouts for newer benefits and personalized Q&A sessions to reduce fatigue and increase understanding. Ongoing education beyond the enrollment window can further strengthen engagement and help employees maximize the value of their selected benefits.

Merger talks between AstraZeneca, Bristol Myers are off — report

By Max Gelman – So much for that. AstraZeneca and Bristol Myers Squibb are no longer in discussions on a merger and will not strike a deal, Reuters reported Wednesday morning, likely putting the kibosh — for now — on what would have been one of the largest acquisitions in corporate history. Reuters cited an anonymous “senior source close to the matter.” Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Reported Merger Discussions Ended Without a Deal: Reports earlier this week indicated that AstraZeneca and Bristol Myers Squibb had discussed a potential merger that would have valued the combined company at approximately $400 billion. According to Reuters, those discussions are no longer active, and both companies declined to comment publicly. The reported talks drew significant attention due to the potential size of the combined organization.

2. Market Reaction Reflected Investor Skepticism: Initial reports of the potential merger were met with skepticism from Wall Street analysts and industry observers, many of whom questioned the strategic rationale for combining two large pharmaceutical companies. AstraZeneca shares fell by as much as 9% following the initial report, reflecting investor concerns. After Reuters reported that the discussions had ended, AstraZeneca shares rebounded about 5%, while Bristol Myers Squibb shares declined approximately 1% in early trading.

3. Combined Company Would Have Ranked Among the Industry’s Largest: A merged AstraZeneca and Bristol Myers Squibb would have created one of the world's largest pharmaceutical companies by market capitalization. At an estimated value of $400 billion, the combined company would have trailed only Eli Lilly, Johnson & Johnson, and AbbVie in market value. The scale of the proposed transaction highlighted the continued focus on consolidation among major pharmaceutical manufacturers.

Why tackling student loan debt will pay off

By Jeni Burckart – Millions of American workers carry student loan debt that strains their monthly budgets, leaving little take-home pay for life's essentials — groceries, rent, healthcare — and creating significant financial stress. This financial pressure doesn't stay at home but follows employees into the workplace. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Student debt is undermining focus and performance: New national research cited in the article shows that 55% of full-time U.S. employees feel their employer either does not understand or has not meaningfully addressed student loan pressures. Additionally, 72% say financial stress affects their ability to concentrate at work. Younger workers are particularly affected, with 84% of Gen Z and 76% of millennials reporting that loan-related stress impacts their focus. The data suggests that student debt is not just a personal issue but a workplace productivity concern.

2. Policy changes may intensify financial strain: The article outlines several federal policy shifts, including the phaseout of certain income-driven repayment plans, new annual borrowing limits and the elimination of the Grad PLUS loan program. Administrative wage garnishment is also set to resume, allowing up to 15% of disposable income to be collected without a court order. Nearly 29% of borrowers are already delinquent and more than 7.7 million are in default, with another quarter at risk of falling into default soon. These developments are expected to deepen financial hardship for many employees.

3. Targeted employer benefits can improve retention: Nearly 80% of full-time workers say student loan support would boost their motivation, and 60% say it would influence their decision to remain with their employer. The article argues that direct student loan repayment assistance and upfront tuition coverage are more effective than simple salary increases, partly due to tax advantages. Employer contributions of up to $5,250 per year can be made on a pretax basis, increasing their relative value compared to taxable compensation. By offering structured support and guidance, employers can reduce turnover while addressing a major source of employee stress.

Judge signs off on Teva's $35M settlement over delayed inhaler generics

By Zachary Brennan – A Massachusetts federal judge on Wednesday approved a $35 million settlement between Teva Pharmaceuticals and a handful of healthcare funds over allegations the company delayed generic versions of its asthma inhalers, causing higher prices. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Teva Agrees to Settlement and Patent Delisting: Teva reached a settlement in a long-running legal case that requires the company to remove all six patents for its QVAR asthma inhaler from the FDA’s Orange Book. The patents had been challenged by plaintiffs representing pension and benefit funds for groups including iron workers, Teamsters, police officers, and firefighters. Teva had already completed the patent delisting before the settlement was finalized.

2. Generic Inhaler Competition Continues to Face Barriers: The settlement comes amid ongoing challenges for generic inhaler manufacturers, despite the expiration of patents on many branded inhalers. Industry observers have cited FDA regulatory requirements, extensive patent portfolios surrounding brand-name products, and high manufacturing and development costs as key obstacles to greater generic competition. A separate 2024 federal court ruling also found that five other Teva inhaler patents had been improperly listed in the FDA’s Orange Book.

3. Asthma Inhaler Pricing Remains Under Scrutiny: The case highlights broader concerns about the cost of asthma medications in the U.S. compared with other countries. In 2024, Senator Bernie Sanders and other lawmakers questioned Teva and other inhaler manufacturers over pricing, noting that QVAR RediHaler was sold for approximately $286 in the U.S. compared with about $9 in Germany. The settlement itself addresses patent listings rather than product pricing, but it occurs amid continued policy attention on inhaler affordability and market competition.